A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : pCR / pathological complete response

[Related PubMed/MEDLINE]
Total Number of Papers: 3786
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   pCR  (>> Co-occurring Abbreviation)
Long Form:   pathological complete response
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients. ALN, DCE, NAC
2023 A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. CRT, LARC
2023 A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer. DFS, LARC
2023 A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). BC, C1D15, CCCA, PLT
2023 Abbreviated Versus Full-Protocol MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment: Diagnostic Performance by General and Breast Radiologists. NAC
2023 Accuracy of Preoperative Contrast-enhanced Cone Beam Breast CT in Assessment of Residual Tumor after Neoadjuvant Chemotherapy: A Comparative Study with Breast MRI. CE-CBBCT, DCIS, ICC, NAC
2023 Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients. DWI, NACT, ROI
2023 Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy. CRT, ESCC, HR, OS, PD-L1, RFS, Siglec-15, TCs
2023 Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma. IMRT, LPS, PLPS, RT
10  2023 Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case. FISH, ICIs, IHC, NUT, PD-L1
11  2023 Clinical significance of adjuvant chemotherapy for pathological complete response rectal cancer patients with acellular mucin pools after neoadjuvant chemoradiotherapy. ACT, CRT, DFS, LARC
12  2023 Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. CI, GC/GEJC, ICIs, MPR, NACT, PD-1, PD-L1, RCTs, TRAEs
13  2023 Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer. HER2, HR, NST
14  2023 Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma. CI, ESCC, ICIs, nabTP, OR
15  2023 Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer. IHC, NAST, OS
16  2023 CT Radiomics for Predicting Pathological Complete Response of Axillary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy: A Prospective Study. CT, LNs, NAC
17  2023 De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. ACT, EBC, ET
18  2023 Deep learning radiomic analysis of DCE-MRI combined with clinical characteristics predicts pathological complete response to neoadjuvant chemotherapy in breast cancer. AUC, DCE-MRI, DLR, NAC
19  2023 Development and Assessment of a Novel Core Biopsy-Based Prediction Model for Pathological Complete Response to Neoadjuvant Chemotherapy in Women with Breast Cancer. AUC, BC, cN, cT, DCA, ER, NAC
20  2023 Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients. BC, ddPCR, NACT, NGS
21  2023 Durvalumab and pet-directed chemoradiation in locally advanced esophageal adenocarcinoma - a phase ib/ii study. ---
22  2023 DWI-MR and PET-CT Functional Imaging for Boost Tumor Volume Delineation in Neoadjuvant Rectal Cancer Treatment. DWI, GTV, LARC, MR, PET-CT
23  2023 Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab for locally advanced esophageal cancer using 18F-FDG PET-CT imaging: a prospective cohort study. AC, CRT, LAEC, PPV, RD, SCC, TRG
24  2023 Early versus delayed surgery following neoadjuvant chemoradiation for esophageal cancer: a systematic review and meta-analysis. HR, nCRT, OR, OS
25  2023 Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment-a retrospective cohort study. ER, FISH, HER2, HER2/CEP17, IHC, PgR, TNM
26  2023 Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world. DCR, MPR, NSCLC, ORR
27  2023 Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis. MPR, NICRT, NICT, TRAEs
28  2023 Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study. AJCC, BC, HER2, HR
29  2023 Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study. ER, HER2, NACT, PgR
30  2023 End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. EFS, HR, miRNAs
31  2023 Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes. AA, BC, TME, TNBC
32  2023 HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. BC, IHC, ISH, NACT, OS, RFS
33  2023 High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. CI, ctDNA, PFS, UC
34  2023 Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy. HR, NAC
35  2023 Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial. HRD
36  2023 Impacts of HER2 Immunohistochemical Scores on Response and Outcomes of HER2-Positive Breast Cancers after Neoadjuvant Therapy. DFS, HER2, IHC, ISH, NST, OS
37  2023 Integrated Intensified Chemoradiation in the Setting of Total Neoadjuvant Therapy (TNT) in Patients with Locally Advanced Rectal Cancer: A Retrospective Single-Arm Study on Feasibility and Efficacy. CONCT, CRT, DFS, ICT, LCRT, TNT
38  2023 Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis. OS, PFS, TTS
39  2023 Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. BC, BCS, LRR, NAIs, NCT
40  2023 Machine learning with textural analysis of longitudinal multiparametric MRI and molecular subtypes accurately predicts pathologic complete response in patients with invasive breast cancer. AUC, XGBoost
41  2023 Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study. BC, MetS, NAC, NCEP ATP III
42  2023 MRI-Based Radiomic Models Outperform Radiologists in Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. AUC, LARC, nCRT
43  2023 Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. MPR, TLND
44  2023 Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review. ALK, CT, MPR, NGS, PCNB, PR
45  2023 Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. AEs, DFS, ORR, TNBC
46  2023 Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study. NAC, TN
47  2023 Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). AE, BC, EC, HER2, nab-PTX, NAC, Pmab, PR, RR, TILs, Tmab
48  2023 Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. CI, HCC, ICIs, MPR, OR
49  2023 Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma. EFS, LAEC, MPR, NCT, nICT, PTR, TRG
50  2023 Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial. ESCC, MPR, TMB, TRAEs
51  2023 Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. ICIs, MPR
52  2023 Nipple-Sparing Mastectomy After Neoadjuvant Chemotherapy: Definitive Results with a Long-Term Follow-Up Evaluation. LRRs, NAC, NACT, NSM
53  2023 Omission of axillary sentinel lymph node biopsy in early invasive breast cancer. BCS, NAST, SLNB
54  2023 Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. DTCs, IE/FC, NAC, RCB
55  2023 PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials. BCR, CA, CR, DD, HR, ORR, OS, PD, PFS, RR, SD, TNBC
56  2023 Pathological complete response and oncological outcomes in locally advanced breast cancers treated with neoadjuvant radiotherapy: an Australian perspective. NART
57  2023 Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report. ICI, LACRC, NIT
58  2023 Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study. AEs, DCR, ESCC, iPR, iSD, MPR, ORR, PFS
59  2023 Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report. PCa, RP
60  2023 Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer. NeoT
61  2023 Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy. AEs, MRI, PBI, SABR
62  2023 Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data. BCS, DFS, LNs, LVI, NAC, OS, ROC, SJTU-BCDB, US
63  2023 Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. AUCs, DCE, NAST, TNBC
64  2023 Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer. ALNMs, NCT, SER
65  2023 Predictive value of 18F-FDG PET/CT-based radiomics model for neoadjuvant chemotherapy efficacy in breast cancer: a multi-scanner/center study with external validation. NAC, TLR, VOI
66  2023 Predictive value of modified MRI-based split scar sign (mrSSS) score for pathological complete response after neoadjuvant chemoradiotherapy for patients with rectal cancer. DWI, mrSSS, mrTRG, nCRT, T2WI
67  2023 Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer. AUC, DCA, ESCC, LASSO, nICT, ROC, SII
68  2023 Preoperative Radiochemotherapy in Rectal Cancer: Is There an Impact of Oxaliplatin on Pathologic Complete Response and Survival Rates under "Real World" Conditions? DFS, nRCT, OS, PSM, pts
69  2023 Prognostic analysis of three forms of Ki-67 in patients with breast cancer with non-pathological complete response before and after neoadjuvant systemic treatment. DFS, Ki-67B, Ki-67T, NST
70  2023 Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. CALGB, EFS, TILs
71  2023 Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response. NAC, OS, RFS, TME, TNBC
72  2023 Radiomic features derived from pretherapeutic MRI predict chemoradiation response in locally advanced rectal cancer. CRT, LARC, MR
73  2023 Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC. aHR, aOR, EBC, OS, TNBC
74  2023 Regional radiotherapy after primary systemic treatment for cN+ breast cancer patients. ALND, LNTB, PST, RNI, RR, SLNB
75  2023 STARD3: A New Biomarker in HER2-Positive Breast Cancer. NST
76  2023 Strategies to Optimize Treatment for Locally Advanced Rectal Cancer. LARC
77  2023 Stromal grading predicts pathologic complete response and prognosis in triple-negative breast cancer. NAC, TME, TNBC
78  2023 Systemic immune mediators reflect tumour-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer. AUC, BC, TILs, TNBC
79  2023 Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. BC, CI, EFS, OS
80  2023 Textural Analysis as a Predictive Biomarker in Rectal Cancer. CRC, MRTA, nCRT, TA
81  2023 The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial. cCR, NAC
82  2023 The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials. BC, CBR, DCR, DRFS, ET, IDFS, ORR, OS, PFS, RR
83  2023 The effects of neoadjuvant zoledronic acid in breast cancer patients: A meta-analysis of randomized controlled trials. BC, RCTs, RR, ZA
84  2023 The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study. AEs, bpCR, HER2, ORR, TKI
85  2023 The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy. DFS, FDG, mOS, PET/CT, PST
86  2023 The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. BC, C-index, NAC, NLR, OS
87  2023 The prognostic values of FOXP3+ tumor-infiltrating T cells in breast cancer: a systematic review and meta-analysis. CI, FOXP3+, HR, OR, OS, TILs, Treg
88  2023 The reduction of 18F-FDG uptake ability of tumor tissue after neoadjuvant chemoradiotherapy in locally advanced rectal cancer can effectively reflect the degree of tumor regression. 18F-FDG PET-CT, AUC, GR, LARC, nCRT, near-pCR, NPVs, PPVs, RI, TME
89  2023 The Relationship among Bowel [18]F-FDG PET Uptake, Pathological Complete Response, and Eating Habits in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. BC, FDG, NAC, PET/CT
90  2023 The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer. DFS, HER2, LABC, NAC
91  2023 The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas. CTAs, RCB, TNBCs
92  2023 Time Course Changes of Synthetic Relaxation Time During Neoadjuvant Chemotherapy in Breast Cancer: The Optimal Parameter for Treatment Response Evaluation. AUC, NAC, OR, PD, ROC, syMRI
93  2023 Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series. AR, ARPIs, BED, P-SABR, t-NEPC
94  2023 Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. NAC, TNBC
95  2023 Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel-based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer. AUC, HDL-C, MPR, NCIO, NSCLC, OR, TC
96  2023 Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response. EC, NST, PR
97  2023 [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer]. ECOG, IMRT, nCRT, SCRT-TNT, TME
98  2022 "This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients". FNR, NACT, SNB
99  2022 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer. CT, FDG, FOXP3, PD-1, PD-L1, PET, TIL, TIME, TNBC
100  2022 A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. 10-miRNA RS, AUC, DFS, HER2, HR, NAC, PR